Investor Alert

Denali Therapeutics Inc.



After Hours

 --Quotes are delayed by 20 min

Jan 24, 2022, 6:08 p.m.





-0.43 -1.24%


Volume 40,184

Quotes are delayed by 20 min


Previous close

$ 32.36

$ 34.76


+2.40 +7.42%

Day low

Day high




52 week low

52 week high




Nancy A. Thornberry

Presently, Nancy A. Thornberry holds the position of Chief Executive Officer & Director at Kallyope, Inc. She is also on the board of Abide Therapeutics, Inc., Intarcia Therapeutics, Inc., Schrödinger, Inc. and Denali Therapeutics, Inc.

In her past career Ms. Thornberry occupied the position of Senior VP, Head-Diabetes & Endocrinology at Merck & Co., Inc. and Principal at Merck Research Laboratories Massachusetts LLC (a subsidiary of Merck & Co., Inc.).

Nancy A. Thornberry received an undergraduate degree from Muhlenberg College.


Date Shares Transaction Value
01/08/2022 627   Award at $0 per share. 0

Officers and Executives

Dr. Ryan J. Watts
President, Chief Executive Officer & Director
Dr. Alexander O. Schuth
Chief Operating Officer & Secretary
Mr. Steve E. Krognes
Treasurer, Chief Financial & Accounting Officer
Dr. Joe Lewcock
Chief Scientific Officer
Dr. Carole Ho
Chief Medical Officer & Head-Development
Dr. Dana Andersen
CTO & Chief Manufacturing Officer
Ms. Katie Peng
Chief Commercial Officer
Dr. Laura G. Hansen
Vice President-Investor Relations
Ms. Cindy Dunkle
Chief People Officer
Dr. Chris Walsh
Associate General Counsel
Ms. Erica Kratz
Vice President-Regulatory
Dr. Vicki L. Sato
Non-Executive Chairman
Ms. Nancy A. Thornberry
Independent Director
Dr. Marc Tessier-Lavigne
Independent Director
Dr. Douglas G. Cole
Independent Director
Mr. Jay T. Flatley
Independent Director
Mr. Robert Taylor Nelsen
Independent Director
Dr. David Paul Schenkein
Independent Director
Mr. Peter S. Klein
Independent Director
Ms. Jennifer E. Cook
Independent Director
Link to MarketWatch's Slice.